Guideline for opioid therapy and chronic noncancer pain
- PMID: 28483845
- PMCID: PMC5422149
- DOI: 10.1503/cmaj.170363
Guideline for opioid therapy and chronic noncancer pain
Conflict of interest statement
Competing interests: D. Norm Buckley and Jason Busse report grants from Health Canada during the conduct of the study. Jason Busse received grants from the Canadian Institutes of Health Research (CIHR) during the conduct of the study. D. Norm Buckley reports grants from Purdue Pharma and Janssen Inc. outside the submitted work. Chris Cull received personal fees from Indivior. David Juurlink reports grants from CIHR and from the Ontario Ministry of Health and Long-Term Care, and personal fees outside the submitted work. Sol Stern was a member of advisory boards for Astra Zeneca, Bristol-Myers Squibb and Johnson and Johnson; received fees for expert opinions from the Canadian Medical Protective Association; received consulting fees from mdBriefCase.com, Ethypharm and Sea Courses; and received honoraria for Continuing Medical Education presentations from Purdue Pharma and Paladin. No other competing interests were declared.
Comment in
-
New Canadian guidance on opioid use for chronic pain: necessary but not sufficient.CMAJ. 2017 May 8;189(18):E650-E651. doi: 10.1503/cmaj.170431. CMAJ. 2017. PMID: 28483843 Free PMC article. No abstract available.
-
Sensible approaches to manage the current opioid crisis.CMAJ. 2017 Sep 18;189(37):E1197. doi: 10.1503/cmaj.733161. CMAJ. 2017. PMID: 28923801 Free PMC article. No abstract available.
-
Inconsistencies in the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain.CMAJ. 2017 Oct 2;189(39):E1233. doi: 10.1503/cmaj.733244. CMAJ. 2017. PMID: 28970262 Free PMC article. No abstract available.
-
The authors respond to "Inconsistencies in the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain".CMAJ. 2017 Oct 2;189(39):E1234-E1235. doi: 10.1503/cmaj.733313. CMAJ. 2017. PMID: 28970263 Free PMC article. No abstract available.
-
Opioid warning label.CMAJ. 2017 Oct 23;189(42):E1318. doi: 10.1503/cmaj.733320. CMAJ. 2017. PMID: 29061858 Free PMC article. No abstract available.
-
Response to "Opioid warning label".CMAJ. 2017 Oct 23;189(42):E1319. doi: 10.1503/cmaj.733337. CMAJ. 2017. PMID: 29061859 Free PMC article. No abstract available.
-
The 2017 Canadian opioid guideline: already time for an overhaul.CMAJ. 2018 Mar 12;190(10):E300. doi: 10.1503/cmaj.68662. CMAJ. 2018. PMID: 29530873 Free PMC article. No abstract available.
-
The authors respond to "The 2017 Canadian opioid guideline: already time for an overhaul".CMAJ. 2018 Mar 12;190(10):E301. doi: 10.1503/cmaj.68675. CMAJ. 2018. PMID: 29530874 Free PMC article. No abstract available.
References
-
- Merskey H, Bogduk NTask Force on Taxonomy of the International Association for the Study of Pain. Classification of chronic pain, second edition (revised). Seattle (WA): International Association for the Study of Pain; 1994.
-
- Reitsma ML, Tranmer JE, Buchanan DM, et al. The prevalence of chronic pain and pain-related interference in the Canadian population from 1994 to 2008. Chronic Dis Inj Can 2011;31:157–64. - PubMed
-
- Hogan ME, Taddio A, Katz J, et al. Health utilities in people with chronic pain using a population-level survey and linked health care administrative data. Pain 2017;158:408–16. - PubMed
-
- Loeser JD. Economic implications of pain management. Acta Anaesthesiol Scand 1999;43:957–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical